Generic Medicine Info
Indications and Dosage
Anaemia, Breast cancer in postmenopausal women, Catabolic disorders, Osteopetrosis
Adult: 50 mg every 2-3 wk.

Vascular manifestations of Behcet's syndrome
Adult: 10 mg daily.

Hereditary angioedema
Adult: Initially, 2.5-10 mg daily, reduced according to response. Maintenance: 2 mg daily or on alternate days or 2.5 mg 3 times wkly.
Child: <6 yr: 1 mg daily; 6-12 yr: Up to 2 mg daily.
Pregnancy and lactation; carcinoma of prostate or breast in men, hypercalcaemia, hypercalciuria, porphyria, severe hepatic impairment.
Special Precautions
Patients with cardiac, renal or hepatic disease, epilepsy or DM. Children, elderly. Monitor liver function, haematocrit and haemoglobin concentrations. Not recommended for treatment of hereditary angioedema in premenopausal women.
Adverse Reactions
Peliosis hepatis, premature epiphyseal closure, cholestatic jaundice, virilism, impotence, priapism, testicular atrophy, gynaecomastia, prostatic hyperplasia, decreased libido, hirsutism, menstrual irregularities; oedema, acne.
Potentially Fatal: Hepatic necrosis, hepatocellular carcinoma.
Drug Interactions
Enhances activity of insulin, sulfonylureas, levothyroxine and anticoagulants e.g. warfarin. May cause resistance to the effects of neuromuscular blockers.
Lab Interference
May interfere with laboratory tests for glucose tolerance and thyroid function.
Mechanism of Action: Stanozolol is a structural analogue of testosterone which increases collagen production and decreases the anti-anabolic action of cortisone. It is also reported to reduce fibrin deposition. It corrects the formation of kinin or kinin-like factors which may be associated with oedema and swelling seen in hereditary angioedema.
Metabolism: Hepatic.
Excretion: Urine (90%), faeces (6%).
MIMS Class
Anabolic Agents
Disclaimer: This information is independently developed by MIMS based on Stanozolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in